| Contact (Matrix/Element) | https://matrix.to/#/@psychedelicmentalhealth:matrix.org |
| Join the Psychedelic Institute | https://psychedelicmentalhealth.net/?v=1739633426043#/portal/signup |
| INSTITUTO PSICODÉLICO DE SALUD MENTAL Y TERAPIA FAMILIAR | https://institutopsicodelico.org |
Traditional theories suggest people with addiction simply stop caring about negative consequences. However, a new Yale study reveals that severe substance users actually struggle to consistently apply what they've learned about costs to their future decisions.
Attacks on trans people are not isolated incidents but rather the visible manifestation of a transphobia that is much more widespread than is often perceived. A new study by a research team from the…
A placebo-controlled experiment reveals how psilocybin changes human time perception. By testing volunteers on a visual timing task, researchers found the psychedelic compound causes people to underestimate durations and feel time passing much slower than normal.
Sporadic recreational use of magic mushrooms and LSD does not damage memory or attention, a new study finds. Instead, young adults who occasionally use classic psychedelics display a distinct advantage in shifting problem-solving strategies and adapting to new rules.
Ketamine holds promise for the treatment of post-traumatic stress disorder (PTSD), but challenges remain in delivery and sustained effects. This controlled study evaluates a novel intranasal formulation, employing AmyloLipid nanovesicles (ALN) to enhance ketamine's therapeutic efficacy in a predator …
Neuroimaging techniques have a rightful place in the field of psychiatry. They are essential for differential diagnosis, especially when the psychiatric presentation is atypical. Furthermore, they associate brain dysfunction with psychiatric disorders, but they cannot yet provide a definitive psychi …
Neuroimaging techniques have a rightful place in the field of psychiatry. They are essential for differential diagnosis, especially when the psychiatric presentation is atypical. Furthermore, they associate brain dysfunction with psychiatric disorders, but they cannot yet provide a definitive psychi …
Twenty-four hours after administration, ketamine exerts rapid and robust antidepressant effects that are thought to be mediated by activation of the mechanistic target of rapamycin complex 1 (mTORC1). To test this hypothesis, depressed patients were pretreated with rapamycin, an mTORC1 inhibitor, prior to receiving ketamine. Twenty patients suffering a major depressive episode were randomized to pretreatment with oral rapamycin (6 mg) or placebo 2 h prior to the intravenous administration of ketamine 0.5 mg/kg in a double-blind cross-over design with treatment days separated by at least 2 weeks. Depression severity was assessed using Montgomery–Åsberg Depression Rating Scale (MADRS). Rapamycin pretreatment did not alter the antidepressant effects of ketamine at the 24-h timepoint. Over the subsequent 2-weeks, we found a significant treatment by time interaction (F(8,245) = 2.02, p = 0.04), suggesting a prolongation of the antidepressant effects of ketamine by rapamycin. Two weeks following ketamine administration, we found higher response (41%) and remission rates (29%) following rapamycin + ketamine compared to placebo + ketamine (13%, p = 0.04, and 7%, p = 0.003, respectively). In summary, single dose rapamycin pretreatment failed to block the antidepressant effects of ketamine, but it prolonged ketamine’s antidepressant effects. This observation raises questions about the role of systemic vs. local blockade of mTORC1 in the antidepressant effects of ketamine, provides preliminary evidence that rapamycin may extend the benefits of ketamine, and thereby potentially sheds light on mechanisms that contribute to depression relapse after ketamine administration.
Psychedelic Institute Project
